Stem Cells Clear Brain Amyloid by Supercharging Neutrophil Mitochondria

Cerebral amyloid angiopathy (CAA) is the leading age-related small-vessel brain disease, characterized by amyloid-beta (Aβ) deposition in cerebral vessel walls, progressive neuroinflammation, blood-brain barrier (BBB) breakdown, and cognitive decline. No disease-modifying therapies exist; current care is purely symptomatic. Because CAA shares key pathological features with Alzheimer's disease—where mesenchymal stem cell (MSC) therapy has shown promise—the authors hypothesized that BM-MSCs might similarly remodel the immune environment in CAA.

Using 8-month-old Tg-SwDI/B transgenic mice (a well-validated CAA model carrying three familial amyloid mutations), the team administered two intravenous doses of human BM-MSCs (2×10⁶ cells each, 3 days apart) and assessed outcomes 7–11 days later. Treated mice showed significantly improved performance in both the novel object recognition test and the Morris water maze, indicating rescued spatial and recognition memory. Immunofluorescence and molecular analyses confirmed reduced Aβ deposition, lower neuroinflammatory marker expression, and maintained BBB integrity compared with vehicle-treated Tg-SwDI/B controls.

The mechanistic core of the study centers on neutrophil mitocytosis. BM-MSCs form membrane-bound organelles called migrasomes during cell migration. The authors demonstrated that BM-MSC-derived migrasomes deliver functional mitochondria to neutrophils. This mitochondrial top-up triggers neutrophils to expel their own damaged mitochondria outward via their own migrasomes—mitocytosis—thereby restoring mitochondrial membrane potential and respiratory capacity. Blocking migrasome formation with blebbistatin abolished this protective transfer, confirming mechanistic specificity. Mitochondrially healthy neutrophils generated fewer reactive oxygen species and formed fewer neutrophil extracellular traps (NETs), both of which drive CAA-associated vascular damage and neuroinflammation.

The downstream consequence was enhanced immune resolution. Neutrophil-derived migrasomes carrying expelled mitochondrial cargo were shown to prime macrophages, boosting their efferocytosis (clearance of apoptotic neutrophils) and phagocytosis of Aβ. In organotypic brain slice cultures and in vivo, BM-MSC-treated animals exhibited greater macrophage-mediated scavenging of both cellular debris and amyloid deposits. This creates a virtuous cycle: stem cells refresh neutrophil mitochondria → neutrophils expel damage, reduce NET formation, and signal macrophages → macrophages clear Aβ and dead neutrophils → neuroinflammation and vascular amyloid burden fall.

The study is the first to link BM-MSC therapy to neutrophil mitocytosis in a neurovascular disease context and positions migrasome-mediated mitochondrial quality control as a druggable axis in CAA. Limitations include the short post-treatment window (11 days), exclusive use of male mice, and the translational gap between mouse models and human CAA, which warrants cautious interpretation before clinical extrapolation.